Document:

<PAGE>   1
                                                                    EXHIBIT 10.4

                        LICENSE AND SUBLICENSE AGREEMENT

     THIS AGREEMENT (the "Agreement"), is made and effective this 18th day of
January, 2001, by and between HTS Biosystems, Inc., a Minnesota Corporation
having its principal office at 92 South Street, Hopkinton, Massachusetts, the
United States of America ("HTS") and Mitsubishi Chemical Corporation, a Japanese
corporation having its principal office at 5-2, Marunouchi 2-chome, Chiyoda-ku,
Tokyo, Japan ("MCC").

                                    RECITALS

     WHEREAS, HTS has exclusively licensed or sublicensed HTS Patents (defined
in Paragraph 1.7) listed in Schedule A from Applied Biosystems Inc., with the
right to grant sublicenses and HTS is willing to exclusively sublicense the HTS
Patents to MCC for the Field of Research Applications (defined in Paragraph 1.4)
in Japan and MCC wishes to obtain an exclusive sublicense to the HITS Patents
for the Field of Research Applications in Japan;

     WHEREAS, HTS is developing HTS Products (defined in Paragraph 1.8) and if
HTS Products are successfully developed, HITS wishes to have MCC exclusively
distribute HTS Products in Japan and MCC wishes to exclusively distribute HTS
Products in Japan under the reasonable terms and conditions to be mutually
agreed upon between the parties in the separate distribution agreement
("Distribution Agreement");

     WHEREAS, MCC will develop MCC Technology (defined in Paragraph 1.13) and
MCC Improvement (defined in Paragraph 1.14) and MCC wishes to non-exclusively
license or sublicense, as the case may be, MCC Technology and non-exclusively
license MCC Improvements to HTS in Non-Pacific Rim Territories (defined in
Paragraph 1.19) and HTS wishes to obtain such licenses or sublicenses; and

     WHEREAS, MCC may develop MCC Products (defined in Paragraph 1.12) and MCC
wishes to have HITS exclusively distribute MCC Products in Non-Pacific Rim
Territories and HTS desires to exclusively distribute MCC products in
Non-Pacific Rim Territories under the reasonable terms and conditions to be
mutually agreed upon between the parties in a separate agreement ("MCC Products
Distribution Agreement");

     NOW, THEREFORE, in consideration of these premises, and the mutual
covenants and agreements hereinafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties agree as follows:

<PAGE>   2

I. DEFINITIONS

     For the purposes of interpreting this Agreement, the following definitions
will apply and whenever appropriate, terms used in the singular will also
include the plural and vice versa:

     1.1  Chip means a substrate which contains a grating pursuant to the
          Grating SPR Technology and is coated with a conductive surface.

     1.2  Effective Date means January 18, 2001.

     1.3  Eamed Royalty means the royalty payable on the Net Sales from
          Products.

     1.4  Field of Research Applications means the field of target discovery and
          validation for pharmaceutical and diagnostic research; the Field of
          Research Applications expressly excludes the Medical Diagnostics Field
          (defined in Paragraph 1.15), food testing applications and
          environmental testing applications.

     1.5  Flow Cell means a device which allows liquids to flow through it and
          consist of a Chip and has an optically clear cover slip which is
          attached to the Chip by a means that allows for fluid flow
          therethrough.

     1.6  Grating SPR Technology means the use of thin conductive films on a
          surface or surfaces of a grating or other diffracting substrate to
          conduct chemical analysis.

     1.7  HTS Patents means those patents that HTS has exclusively licensed or
          sublicensed from Applied Biosystems Inc. and which HTS has the right
          to sublicense. The HTS Patents are listed in Schedule A of this
          Agreement.

     1.8  HTS Products means Instruments, Chips, Flow Cells and Peripheral
          Equipment for use in the Field of Research Applications developed or
          to be developed by HTS using Grating SPR Technology covered by one or
          more Valid Claim of the HTS Patents.

     1.9  HTS SPR Array System means grating coupled SPR detection systems
          capable of reading distinct detection sites on a 1cm x 1cm Chip and
          will include future upgrades or versions of such original system with
          the first HTS SPR Array Systems being capable of reading up to 400
          distinct detection sites.

                                       2

<PAGE>   3

     1.10 HTS Technology means any technology including and relating to the
          Grating SPR Technology owned by HTS as of the effective date of this
          Agreement and to be developed during the term of this Agreement that
          (i) subject to HTS's, reasonable judgement will be useful for the
          development of MCC Products and/or HTS Products for the Field of
          Research Applications and (ii) HTS is not restricted from licensing or
          sublicensing the technology by an agreement HTS may have with a third
          party.

     1.11 Instrument means a device that reads the events that occur in a Chip
          for use in the Field of Research Applications using Grating SPR
          Technology covered by one or more Valid Claim of the HTS Patents.

     1.12 MCC Products means Instruments, Chips, Flow Cells and Peripheral
          Equipment for the Field of Research Applications to be developed by
          MCC using Grating SPR Technology covered by one or more Valid Claim
          of the HTS Patents.

     1.13 MCC Technology means any technology owned or controlled by MCC's
          diagnostic R&D sector as of the effective date of this Agreement and
          to be developed by MCC's diagnostic R&D sector during the term of this
          Agreement that (i) will, subject to MCC's reasonable judgement, be
          useful for the development of MCC Products and/or HTS Products for the
          Field of Research Applications and (ii) MCC is not restricted from
          licensing or sublicensing the technology by an agreement MCC may have
          with a third party.

     1.14 MCC Improvement means any technology that is an improvement of the HTS
          Technology (defined in Paragraph 1.10) obtained by MCC during the term
          of this Agreement that (i) is useful for the Field of Research
          Applications and (ii) MCC is not restricted from licensing or
          sublicensing the technology by an agreement MCC may have with a third
          party.

     1.15 Medical Diagnostics Field means those fields, the applications and
          products which under current laws and regulations of the United States
          would require approval of the United States Food and Drug
          Administration if the application or product incorporating the
          application were sold for clinical use in the United States.

     1.16 Net Sales means the total amount invoiced by either MCC or HTS, or any
          sublicensee, for sales of its own Products to third parties after a
          deduction of any: (i) sales, use or excise taxes; (ii) freight or
          shipping charges; (iii) duty or insurance included therein; (iv)
          credits or prepayments due to rejections; (v) defects or returns; (vi)
          amounts for trade and quantity discounts actually allowed and taken;
          and (vii) packaging costs.

                                        3

<PAGE>   4

     1.17 Pacific Rim Territory means the countries of Japan, China, Taiwan,
          Korea, Australia, New Zealand, Indonesia, Singapore and Thailand.

     1.18 Peripheral Equipment means those devices that are sold in conjunction
          with the Instrument and/or Chips, including, but not limited to,
          chemistry coating, sample preparation and Chip handling equipment,
          excluding, however, any other detection instruments that do not use
          the Grating SPR Technology.

     1.19 Non Pacific Rim Territories shall mean the U.S.A., Canada, Mexico and
          other countries of the world that are not in the Pacific Rim Territory
          as defined in Paragraph 1.17.

     1.20 SPR means surface plasmon resonance.

     1.21 The Parties means both HTS and MCC.

     1.22 Valid Claim means an issued claim of a HTS Patents, or a patents to be
          granted on the MCC Technology or MCC Improvement, that has not been
          expired nor has been held invalid or unenforceable by final decision
          of a court of competent jurisdiction from which no appeal has or can
          be taken.

     1.23 Wholly Owned Subsidiary of a party means a corporation, company or
          other entity of which 100% of the voting stock is directly or
          indirectly owned or controlled by HTS or MCC as the case may be.

2. LICENSE GRANTS FROM HTS TO MCC

     2.1  License Grant from HTS to MCC. HTS hereby grants to MCC the sole and
          exclusive license and sublicense under the HTS Patents and HTS
          Technology to develop, manufacture, have manufactured, sell or have
          sold MCC Products for the Field of Research Applications in Japan,
          provided, however, that MCC shall not develop, manufacture or have
          manufactured products which are covered by one or more valid claims of
          the HTS Patents and for which there is a HTS Product commercially
          available from HTS for distribution by MCC under reasonable supply and
          purchase conditions of the Distribution Agreement.

     2.2  Sublicense by MCC. MCC shall not sublicense the rights granted by HTS
          in Paragraph 2.1 except that MCC may sublicense the rights granted in
          Paragraph 2.1 only to Yuka Medias Co. Ltd. ("Yuka"), a Wholly Owned
          Subsidiary of MCC, and/or to another MCC Wholly Owned Subsidiary for
          the Field of Research Applications in Japan.

                                        4

<PAGE>   5

     2.3  Grant-back from MCC to HTS. MCC hereby grants to HTS an exclusive
          license to develop, manufacture, have manufactured, sell or have sold
          the HTS Products incorporating MCC Improvement in Non-Pacific Rim
          Territories for the Field of Research Applications.

3. ROYALTIES, PAYMENTS AND REPORTS

     3.1  Initial Payment. In consideration of the license and sublicense
          granted to MCC pursuant to Paragraph 2.1, MCC shall pay HTS an initial
          payment of one million and five hundred thousands US Dollars
          (US$1,500,000-) within forty-five (45) days from the effective date of
          this Agreement.

     3.2  Royalties on Account of Net Sales by MCC. Subject to the terms of
          this Agreement, in consideration of the license and sublicense
          granted to MCC pursuant to Paragraph 2.1, MCC agrees to pay to HTS an
          Earned Royalty of 7% of annual Net Sales of MCC Products, provided,
          however, that no royalty shall be paid on HTS Products purchased by
          MCC from HTS and resold by MCC under the Distribution Agreement. In
          the event that MCC Products require payment of royalties to a third
          party for technology other than that provided from HTS under this
          Agreement, the Parties agree to discuss a reduction of the royalty
          rate stated in this Paragraph 3.2 to reflect the portion of each
          technology provided in the MCC Product so as to address the issue of
          royalty stacking.

     3.3  Royalties on Account of Net Sales by HTS. Subject to the terms of
          this Agreement, in consideration of the license granted to HTS
          pursuant to Paragraph 2.3, HTS agrees to pay MCC an Earned Royalty of
          7% of annual Net Sales of HTS Products covered by one or more Valid
          Claim of a patent to be granted on the MCC Improvement in a country
          where the HTS Product is sold and such a patent is in force, provided,
          however, that no royalty shall be paid on MCC Products purchased by
          HTS from MCC and resold by HTS under the MCC Products Distribution
          Agreement.

     3.4  Quarterly Royalty Payments. All Earned Royalties due by either party
          to the other party hereunder shall be payable on a calendar quarterly
          basis. Within sixty (60) days after the end of each Calendar Quarter
          during the term of this Agreement, each party owing an Earned Royalty
          under Paragraphs 3.2 or 3.3 shall pay the Earned Royalty owed to the
          other party through the end of the preceding Calendar Quarter and
          shall furnish the other party with a written statement setting forth
          the number of its own Products sold and the Net Sales invoiced during
          such Calendar Quarter, and the resulting amount of the royalty due
          under Paragraphs 3.2 and 3.3.

                                        5
<PAGE>   6

     3.5  Late Payment. A party owing a payment to the other party under any of
          Paragraphs 3.2 and 3.3 shall pay a late payment fee to the owed party
          when payment is not made within the times set forth in Paragraphs 3.4.
          The late payment fee shall be calculated at a variable rate of one
          percent (1%) over the "3 Month T-Bill" as reported in "The Wall Street
          Journal" on the date the payment is due (the "Interest Rate"), on any
          and all amounts that are at any time overdue and payable under this
          Agreement, such interest being calculated on each such overdue amount
          from the date when such amount became due to the date of actual
          payment thereof. Such late payment fee shall be in addition to and not
          in lieu of any and all other rights or remedies that HTS may have
          under this Agreement or law relating to a default by the owing party
          under this Agreement.

     3.6  Records. During the term of this Agreement and for three (3) years
          after termination of this Agreement, the Parties shall at all times
          maintain accurate and up-to-date records containing complete data from
          which amounts due to the other party under this Agreement may be
          readily calculated. Further, the Parties shall preserve and permit
          examination of such records by independent auditors appointed by the
          other party and accepted by itself at reasonable intervals and under
          reasonable conditions during the term of this Agreement and for three
          (3) years thereafter and, upon request, shall supply to the
          independent auditors all information reasonably requested that is
          useful in making a proper audit and verification of the other party's
          performance of its obligations under this Agreement and of any of the
          Parties' sublicensee(s) performance in accordance with the terms of
          this Agreement.

     3.7  Underpayment. If one party determines by audit and inspection of the
          other party's books and records that the other party has failed to pay
          all royalties due under Paragraph 3.2 or 3.3, the other party shall
          pay the party owed one hundred ten percent (110%) of such additional
          royalties as may be due in addition to the interest as provided for in
          Paragraph 3.5. If the amount of underpayment exceeds 5% of the
          royalties due under Paragraph 3.2 or 3.3, then the owed party shall,
          in addition to any other remedies available to it, recover from the
          other party the reasonable costs incurred in making any such audit and
          inspection pursuant to Paragraph 3.8 hereof which revealed such
          shortfall.

     3.8  Payment Currency. All payments by one party to the other party under
          this Agreement shall be made in U.S. Currency. The U.S. currency
          payments hereunder shall be determined on the basis of the telegraphic
          transfer selling (TTS) rate of exchange as reported by Tokyo
          Mitsubishi Bank in effect on the date such payments are due. All
          payments due shall be made without deduction for taxes, assessments,
          or other charges of any kind that may be imposed on a party by any
          government other than that of the United States or Japan. Provided,
          however, either party may deduct from each payment due

                                        6
<PAGE>   7

          hereunder withholding income tax to be levied on such payment in the
          U.S.A. or Japan according to the Treaty between US and Japan for
          Avoidance of Double Taxation and shall furnish the other party
          appropriate tax certificate issued by the tax authority in the U.S.A.
          or Japan.

4. LICENSE GRANTS FROM MCC TO HTS

     4.1  License Grant from MCC to HTS under MCC Technology. If and when MCC
          developed and commercially manufacture and sell the MCC Products which
          incorporated the MCC Technology, then MCC shall promptly notify HTS of
          such fact with sufficient information, data and sample thereof for
          evaluation of such MCC Technology. Upon request from HTS, MCC and HTS
          shall discuss, in good faith, reasonable terms and conditions of
          license of the MCC Technology and enter into the license agreement
          which includes, but not limited to, the following basic conditions;

          (1)  MCC grants to HTS the non-exclusive license to develop,
               manufacture, sell and have sold the HTS Products incorporating
               MCC Technology in Non-Pacific Rim Territories for the Field of
               Research Applications.
          (2)  In consideration of the license granted to HTS pursuant to
               Paragraph 4.1, HTS agrees to pay MCC an Earned Royalty of 7% of
               annual Net Sales of HTS Products covered by one or more Valid
               Claim of a patent to be granted on the MCC Technology or MCC
               Improvement in a country where the HTS Product is sold and such a
               patent is in force, provided, however, that no royalty shall be
               paid on MCC Products purchased by HTS from MCC and resold by HTS
               under the MCC Products Distribution Agreement. In the event, to
               incorporate the MCC Technology into the HTS Products, HTS is
               required to pay royalties to a third party for technology other
               than that provided from MCC under this Agreement, the Parties
               agree to discuss a reduction of the royalty rate stated in this
               Subparagraph (2) to reflect the portion of each technology
               provided in the HTS Product so as to address the issue of royalty
               stacking. In the event that MCC may provide a lower royalty rate
               than provided for in this Subparagraph (2) when MCC grants a
               license to a third party to manufacture, use and sell a product
               directly competing with a HTS Products in a particular country,
               the Earned Royalty rate for Net Sales by HTS of HTS Products in
               that country shall be reduced to equal the lower royalty
               rate.
          (3)  The non-exclusive rights granted to HTS to the MCC Technology
               shall expire upon the expiration of the last of the patents of
               MCC Technology to expire; provided, however, the license shall be
               terminated if HTS has not begun developing, commercializing or
               selling the HTS Products incorporating MCC Technology within one
               (1) year after MCC notifies HTS of any such MCC Technology.
               Beginning six (6) months after MCC notifies HTS of any such MCC
               Technology and continuing every six (6) months, HTS shall provide
               a statement to MCC stating that it is

                                        7

<PAGE>   8

               continuing to develop, commercialize or sell HTS Products
               incorporating MCC Technology or that the MCC Technology is being
               abandoned.

5. TERMS AND TERMINATION

     5.1  Term of Agreement. This Agreement shall commence on the Effective Date
          and shall expire, unless earlier terminated pursuant to Paragraphs
          5.3, 5.4 or 5.5 of this Agreement, upon the expiration of the last of
          the HTS Patents. After the expiration of this Agreement, MCC shall
          have the non-exclusive, royalty-free right (with the right to grant
          sublicense) to use the HTS Technology.

     5.2  Termination of License Grant to HTS Under MCC Improvement.
          Notwithstanding the foregoing Paragraph 5.1, the exclusive license
          granted to HTS to MCC Improvement under Paragraph 2.3 and obligation
          to pay Earned Royalty under Paragraph 3.3 of this Agreement shall
          survive after the expiration of this Agreement and shall expire upon
          the expiration of the last of the patents of MCC Improvement to
          expire; provided, however, the license shall be terminated if HTS has
          not begun developing, commercializing or selling the HTS Products
          incorporating MCC Improvement within one (1) year from the time when
          MCC notifies HTS of any such MCC Improvement. Beginning six (6) months
          after such notification and continuing every six (6) months, HTS shall
          provide a statement to MCC stating that it is continuing to develop,
          commercialize or sell the HTS Products incorporating MCC Improvement
          or that the MCC Improvement is being abandoned.

     5.3  Termination by HTS. If MCC is in material default of any of its
          obligations under this Agreement, HTS shall have the right to
          terminate this Agreement by giving thirty (30) days' written notice of
          termination specifying the reason for termination, provided that such
          notice will be of no effect and termination will not occur if the
          specified default is cured prior to the expiration of said thirty (30)
          day notice period. In the event of any such termination, HTS shall at
          its sole discretion retain rights to use MCC Improvement granted to
          it, by MCC under Paragraph 2.3, unless earlier terminated as provided
          in Paragraph 5.2. In the event that HTS retains the rights under
          Paragraph 2.3 or 4.1, HTS shall continue paying to MCC any Earned
          Royalty as provided under Paragraph 3.3 or 4.1, as the case may be.

     5.4  Termination by MCC. If HTS is in material default of any of its
          obligations under this Agreement, MCC shall have the right to
          terminate this Agreement by giving thirty (30) days' written notice of
          termination specifying the reason for termination, provided that such
          notice will be of no effect and termination will not occur if the
          specified default is cured prior to the expiration of said thirty (30)
          day notice period. In the event of any such termination, MCC shall at
          its sole discretion retain rights to use the HTS

                                       8
<PAGE>   9

          Patents and HTS Technology granted to it by HTS under Paragraph 2.1.
          In the event that MCC retains the rights under Paragraph 2.1, MCC
          shall continue paying to HTS any Earned Royalty as provided under
          Paragraph 3.2.

     5.5  MCC 90 days Termination. MCC may terminate all or a portion of this
          Agreement at any time at will, with or without cause, by giving at
          least ninety (90) days' prior written notice to HTS.

     5.6  Refunds. Termination of this Agreement at any time will not entitle
          either party to a refund of payments of any type made prior to
          termination.

     5.7  Termination Resulting from Government Action. Either party may,
          immediately upon notice, terminate this Agreement in its entirety or
          with respect to any patent license granted under the Agreement if: (1)
          such termination is necessary to comply with an order or official
          request of the government of the terminating party; or (2) normal
          conduct of the business of the other party as a private enterprise
          ceases or is substantially altered as a consequence of action taken by
          governmental or other authority.

     5.8  Continued Obligations. Termination shall not relieve or release either
          party from its obligations to make any payment which may be owing to
          the other party under the terms of this Agreement or from any other
          liability which either party may have to the other arising out of the
          terms of this Agreement.

6. INTELLECTUAL PROPERTY

     6.1  Patent Procurement and Costs. HTS shall be respectively and solely
          responsible for directing prosecution and paying all patent costs and
          expenses (including reasonable attorneys' fees) incurred during the
          term of this Agreement in obtaining, prosecuting, and maintaining any
          of the HTS Patents issued or to be issued under the law of any country
          or jurisdiction identified in Schedule A, including filing,
          prosecution, working and maintenance costs and taxes.

     6.2  Patent Enforcement.

          (1)  In the event that MCC becomes aware of activity on the part of
               any third party which may constitute infringement of HTS Patents
               in Japan, MCC shall give HTS written notice thereof. Subject to
               the License Agreement between HTS and Ares Serono, HTS shall, at
               its sole discretion and expense, have the first exclusive right
               to initiate and thereafter maintain reasonable efforts to prevent
               and abate such infringement, including the initiation of an
               appropriate action for infringement and the taking of such other
               action as it may determine to be necessary or appropriate to
               enforce the HTS Patents. In such event, (i) MCC will execute all
               pleadings,

                                        9
<PAGE>   10

                    documents and other papers necessary or appropriate in
                    conjunction therewith, and (ii) HTS shall receive the full
                    benefits of any action it takes pursuant to this Paragraph,
                    including retaining all sums recovered in any such suit or
                    in settlement thereof.
              (2)   In the event that HTS fails or refuses to take or cause
                    to be taken any such measures against any third party in
                    Japan after six (6) months from the date of receipt of
                    written notice to HTS by MCC of such infringement, MCC may
                    take such legal action in its own name or in the name of
                    HTS (if needed) and at its own expense upon giving fourteen
                    (14) days advance, written notice of its intention to do
                    so. In this case, MCC shall received the full benefits of
                    any action it takes pursuant to this Paragraph 6.2,
                    including retaining all sums recovered in any such suit or
                    in settlement thereof.
              (3)   If either party litigates under this Paragraph 6.2, the
                    other party may, at its option and its cost and expense,
                    participate in meetings with the litigating party and/or
                    its counsel and receive all pleadings, documents and other
                    related papers useful for the purpose of keeping the other
                    party informed of the status of any proceedings commenced
                    by the litigating party.

            6.3  Joint Inventions. Each party shall have an equal, undivided
                 interest in any invention in the Field of Research Application,
                 and any patent thereon, that is jointly made by employees of
                 both Parties. The Parties agree to cooperate in obtaining and
                 maintaining patents on such jointly owned invention and to
                 share equally the expense thereof. Neither party shall grant a
                 license under the jointly owned patent without the prior
                 written consent of the other party.

            6.4  Marking. If requested by a party, the other party shall mark
                 the product(s) it sells, offers to sell or distributes with a
                 notice to the effect that such product(s) is licensed under the
                 applicable Patents.

        7.  CONFIDENTIALITY

            7.1  Confidentiality. The Parties acknowledge that patent
                 applications listed in Schedule A attached hereto, the
                 inventions claimed therein, and all trade secrets and know-how
                 which may be disclosed by the Parties in performance of this
                 Agreement constitute "Confidential Information" of the Parties,
                 subject to the exceptions set forth in Paragraph 7.2. Each
                 party agrees not to disclose or use any of the other party's
                 Confidential Information except as expressly permitted in
                 connection with the exercise of its rights hereunder for five
                 (5) years after respective termination of license granted under
                 this Agreement.

            7.2  The Parties shall not disclose the other party's Confidential
                 Information to any employee or consultant unless such employee
                 or consultant is obligated under a confidentiality agreement to
                 maintain such other party's Confidential Information in strict
                 confidence, and not to use such information other than,

                                       10

<PAGE>   11

                 in accordance with the terms of this Agreement. Each party
                 agrees to hold the other party's Confidential Information
                 in strict confidence and treat it with not less than the
                 same degree of care to avoid disclosure as such party
                 employs with respect to its own information of like
                 importance.

            7.3  Confidential Information shall mean all information provided
                 to a party (the "receiving party") by a party (the "disclosing
                 party") or its employees, agents or consultants, excluding any
                 information which:

             (a)  is or becomes publicly available through no fault of the
                  receiving party; or

             (b)  can be reasonably demonstrated to have been known to the
                  receiving party independently of any disclosure of
                  "Confidential Information" by the disclosing party or its
                  employees, agents or consultants; or

             (c)  is disclosed to the receiving party by a third party who, to
                  the best of the receiving party's knowledge, is lawfully in
                  possession of the same and has the right to make such
                  disclosure; or

             (d)  has been independently developed by the receiving party
                  without reference to the information disclosed to the
                  receiving party by the disclosing party or its employees,
                  agents or consultants.

     8.   INDEMNIFICATION

          8.1   INDEMNIFICATION BY HTS. HTS shall defend, indemnify and hold
                MCC and its shareholders, directors, officers, agents,
                representatives, successors and assigns harmless from and
                against any and all claims, damages, costs (including reasonable
                attorneys' fees), judgments, fines, penalties, losses,
                diminution in value and liabilities of and kind or nature (a)
                arising out of the breach by HTS of any of its warranties,
                representations and covenants under this Agreement.

     9.   REPRESENTATIONS AND WARRANTIES

          9.1   HTS hereby warrants and represents to MCC as follows:

            (a)  HTS is a corporation duly organized, validly existing and in
                 good standing under the laws of the State of Minnesota.

            (b)  This Agreement has been duly authorized, executed and delivered
                 by HTS and constitutes a valid and binding obligation of HTS,
                 enforceable in accordance with its terms, except as rights to
                 indemnification thereunder may be limited by applicable law and
                 except as and to the extent that the enforcement thereof may be
                 limited by bankruptcy,

                                       11

<PAGE>   12

                insolvency, reorganization, moratorium or other similar laws
                relating to or affecting creditors' rights generally or by
                general equitable principles. The execution, delivery and
                performance of this Agreement and the consummation of the
                transactions contemplated thereby have been authorized by all
                necessary corporate action and do not and will not conflict with
                or result in any material breach of any of the provisions of, or
                constitute a material default under, or result in a material
                violation of, or require any authorization, consent or approval,
                under the provisions of any organizational charter, articles,
                bylaw, member control, operating or other agreement, contract or
                instrument to which HTS is bound or affected, or any law,
                statute, rule, regulation, judgment order or decree to which HTS
                is subject.

           (c)  HTS is the sole and exclusive licensee, sublicensee, or owner,
                as the case may be, of all the rights of HTS Patents listed in
                Schedule A and has full right, power and authority to grant the
                rights under this Agreement.

           (d)  All HTS Patents listed in Schedule A are in force having paid
                all necessary maintenance fees. HTS has no knowledge of
                information that would render any of the listed patents invalid
                or unenforceable.

           (e)  HTS has good and marketable title to the HTS Patents free and
                clear of any and all liens, pledges, claims, licenses,
                assignments, conditional sales contracts, agreements or
                encumbrances of any kind that would impair HTS's ability to
                grant the licenses under this Agreement.

           (f)  The use of the HTS Technology granted hereunder and use or sale
                of the HTS Products to be distributed under the Distribution
                Agreement shall be free from and clear of infringement of any
                intellectual property rights owned by third parties.

         9.2   MCC hereby warrants and represents to HTS as follows:

           (a)  MCC is a corporation duly organized, validly existing and in
                good standing under the laws of Japan.

           (b)  This Agreement has been duly authorized executed and delivered
                by MCC and constitutes a valid and binding obligation of MCC,
                enforceable in accordance with its terms, except as rights to
                indemnification thereunder may be limited by applicable law and
                except as the enforcement thereof may be limited by bankruptcy,
                insolvency, reorganization, moratorium or other similar laws
                relating to or affecting creditors' rights generally or by
                general equitable principles. The execution, delivery and
                performance of this Agreement and the consummation of the
                transactions contemplated thereby do not and will not
                conflict with or result in any material breach of any of the
                provisions

                                       12

<PAGE>   13

                of, or constitute a material default under, or result in a
                material violation of, or require any authorization, consent or
                approval, under the provisions of the Laws of Japan or Bylaws or
                other agreement, contract or instrument to which MCC is bound or
                affected, or any law, statute, rule, regulation, judgment order
                or decree to which MCC is subject.

     10.  MISCELLANEOUS

          10.1  Assignment. Either party may assign or otherwise transfer its
                rights and obligations under this Agreement to any successor in
                interest (by merger, share exchange, combination or
                consolidation of any type, operation of Law, purchase or
                otherwise), provided that such assignee or successor agrees to
                be bound by the terms hereof.

          10.2  Entire Agreement. This Agreement, together with the Schedule,
                and the SSA constitutes the entire agreement of the Parties with
                respect to the subject matter hereof and supersedes all previous
                proposals or agreements, oral or written, and all negotiations,
                conversations or discussions heretofore had between the Parties
                related to the subject matter of this Agreement. No modification
                of this Agreement or waiver of any of its terms shall be binding
                upon the Parties unless said modification or waiver is in
                writing, signed by both Parties, and states that it is an
                amendment to this Agreement.

          10.3  Survival. Section 1,4,8,9 and 10 shall survive termination or
                expiration of this Agreement for any reason and continue
                thereafter in full force and effect.

          10.4  Discharge. This Agreement may not be released, discharged,
                abandoned, changed or modified in any manner, except by an
                instrument in writing signed on behalf of each of the Parties to
                this Agreement by their duly authorized representatives.

          10.5  Waiver. The failure of either party to enforce at any time any
                of the provisions of this Agreement shall in no way be construed
                to be a waiver of any such provision, nor in any way to affect
                the validity of this Agreement or any part of it or the right of
                either party after any such failure to enforce each and every
                such provision. No waiver of any breach of this Agreement shall
                be held to be a waiver of any other or subsequent breach.

          10.6  Force Majeure. Neither party shall be responsible for any delay
                or failure in the performance of any obligation hereunder due to
                strikes, lockouts, fires, floods, acts of God, embargoes, wars,
                riots, or act or order of any government or governmental agency.

          10.7  Execution in Counterparts. This Agreement may be executed in one
                or more counterparts, all of which shall be considered one and
                the same agreement,

                                       13

<PAGE>   14

                and shall become a binding agreement when one or more
                counterparts have been signed by each party and delivered to the
                other party.

          10.8  Titles and Headings. The titles and headings to Sections herein
                are inserted for the convenience of reference only and are not
                intended to be a part of or to affect the meaning or
                interpretation of this Agreement.

          10.9  Construction. The Parties agree that the restrictions,
                covenants, agreements and obligations contained in this
                Agreement are reasonable and necessary to protect the legitimate
                interests of the Parties. This Agreement shall be construed
                without regard to any presumption or other rule requiring
                construction hereof against the party causing this Agreement to
                be drafted.

          10.10 Benefit. Nothing in this Agreement, expressed or implied, is
                intended to confer on any person other than the Parties to this
                Agreement or their respective permitted successors or assigns,
                any rights, remedies, obligations or liabilities under or by
                reason of this Agreement.

          10.11 Notices. All notices, statements, reports, requests or other
                communications to a party required or permitted hereunder shall
                be in writing and shall be deemed effective and properly given
                when sent by registered or certified mail, or by confirmed
                facsimile transmission to the person as indicated below or such
                other person as may be designated by MCC or HTS by such notice;

                if to MCC, to:

                Mitsubishi Chemical Corporation.
                5-2, Marunouchi 2-chome,
                Chiyoda-ku, Tokyo 100-0005 Japan
                Attention: General Manager, Life Science Business Initiatives
                Department
                Facsimile number: (03) 3283-5809

                and, if to HTS, to:

                HTS Biosystems, Inc.,
                92 South Street,
                Hopkinton, Massachusetts 55121 U.S.A.
                Attention: CEO
                Facsimile number: (508) 435-4700

                MCC and HTS may change their respective above-specified
                recipient and/or mailing address by notice to the other party
                given in the manner herein prescribed. All notices shall be
                deemed given on the day when actually delivered as provided
                above (if delivered by facsimile) or on the day shown on the
                return receipt (if delivered by mail).

                                       14

<PAGE>   15

         10.12  Severability. If any provision of this Agreement is held invalid
                by a court of competent jurisdiction, the remaining provisions
                shall nonetheless be enforceable according to their terms.
                Further, if any provision is held to be overbroad as written,
                such provision shall be deemed amended to narrow its application
                to the extent necessary to make the provision enforceable
                according to applicable Law and shall be enforced as amended.

         10.13  Governing Law. This Agreement shall be construed in accordance
                with the laws of the State of New York, excluding its choice of
                law provisions. The Parties further agree to submit themselves
                to the non-exclusive jurisdiction of the state and federal
                courts of the State of New York in the event that any dispute
                arises under this Agreement.

         IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed in the manner appropriate to each as of the day and year first above
written.

                              MITSUBISHI CHEMICAL CORPORATION

                              /s/  Kiyoshi Nakayama
                              ----------------------------------------
                              By:  Kiyoshi Nakayama
                              Its: General Manager,
                                   Life Science Business Initiatives Department

                              HTS BIOSYSTEMS, INC.

                              /s/  Gregory G. Freitag
                              ----------------------------------------
                              By:  Gregory G. Freitag
                              Its: Chief Executive Officer

                                       15

<PAGE>   16

                                   SCHEDULE A

                       HTS LICENSED OR SUBLICENSED PATENTS

<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------
 PATENT NO.                         TITLE                            JAPANESE PATENT NO.
------------------------------------------------------------------------------------------
<S>                 <C>                                             <C>
US 4,931,384         Optical Assay Technique (Merlin I)                  JP 1903195
------------------------------------------------------------------------------------------
US 5,118,608         Optical Assay Technique (Merlin I)                  JP 2502222
------------------------------------------------------------------------------------------
US 4,882,288         Assay Technique and Equipment (Merlin II)           JP 1928364
------------------------------------------------------------------------------------------
US 4,992,385         Polymer-Coated Optical Structures and               JP 2528134
                     Methods of Making and Using the Same                JP 2592588
                     (Cellulose Nitrate Films)
------------------------------------------------------------------------------------------
US 4,828,387         Film Measuring Device and Method with               JP 2511057
                     Internal Calibration to Minimize the Effect
                     of Sample Movement (Calibration Notches)
------------------------------------------------------------------------------------------
US 5,310,686         Polymer-Coated Optical Structures (Sensor           JP 2710243
                     Using Photoresist)
------------------------------------------------------------------------------------------
CA 1,302,875         (Waveguide Sensor)                                  JP 2572829
------------------------------------------------------------------------------------------
US 6,093,536         (Enhanced SPR Assay)                                JP 2073383
------------------------------------------------------------------------------------------
                     Optical Array                                   JP Application #
                                                                     JP 2000-524645
------------------------------------------------------------------------------------------
</TABLE>

                                       16<PAGE>   1

                                OPTION AGREEMENT

           THIS AGREEMENT (the "Agreement"), is made and effective this 18th day
of January, 2001, by and between HTS BioSystems, Inc., a Minnesota Corporation
having its principal office at 92 South Street, Hopkinton, Massachusetts, the
United States of America ("HTS") and Mitsubishi Chemical Corporation, a Japanese
corporation having its principal office at 5-2, Marunouchi 2-chome, Chiyoda-ku,
Tokyo, Japan ("MCC").

                                    RECITALS:

           WHEREAS, HTS is engaged in the manufacture and sale of the HTS
Products (as defined in Paragraph 1.8 hereof);

           WHEREAS, HTS is developing HTS SPR Array System (as defined in
Paragraph 1.5 hereof) and wishes to have MCC exclusively distribute HTS Products
in Japan; and

           WHEREAS, MCC wishes to have an option to distribute and resell HTS
Products exclusively in Japan after successful development of the HTS SPR Array
System.

           NOW, THEREFORE, in consideration of these premises, and the mutual
covenants and agreements hereinafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows:

1.     DEFINITIONS

           For the purposes of interpreting this Agreement, the following
definitions will apply and whenever appropriate, terms used in the singular will
also include the plural and vice versa:

1.1.          Chip means a substrate which contains a grating pursuant to the
              Grating SPR Technology and is coated with a conductive surface.

1.2.          Effective Date means January 18, 2001.

1.3.          Exercise Date means the date that MCC notifies HTS in writing to
              exercise MCC's option granted from HTS pursuant to Paragraph 2, in
              accordance with the successful evaluation by MCC of the HTS SPR
              Array System which is delivered from HTS to MCC pursuant to
              Paragraph 3. The performance requirements for the HTS SPR Array
              System is listed in Schedule A

1.4.          Flow Cell means a device which (i) allows liquids to flow through
              it and comprises a base piece which contains a grating pursuant to
              the Grating SPR Technology; (ii) is coated with a conductive
              surface; and (iii) has an optically clear cover slip which is
              attached to the base piece by a means that allows for fluid flow.

1.5.          HTS SPR Array System means grating coupled SPR detection systems
              capable of reading distinct detection sites on a 1cm x 1cm Chip
              and will include future upgrades or versions of such original
              system with the first HTS SPR Array Systems being capable of
              reading up to 400 distinct detection sites.

1.6.          Grating SPR Technology means the use of thin conductive films on a
              surface or surfaces of a grating or other diffracting substrate to
              conduct chemical analysis.

<PAGE>   2

1.7.          HTS Patent means those patents that HTS has exclusively licensed
              or sublicensed from Applied BioSystems Inc. and which HTS has the
              right to sublicense. The HTS Patents are listed in Schedule A of
              this Agreement.

1.8.          HTS Products means Instruments, Chips, Flow Cells and Peripheral
              Equipment for use in the Field of Research Applications developed
              or to be developed by HTS using Grating SPR Technology covered by
              one or more Valid Claims of the HTS Patents.

1.9.          HTS Technology means any Grating SPR technology owned by HTS as of
              the Effective Date and to be developed during the term of this
              Agreement that (i) is useful for the development of MCC Products
              and/or HTS Products for the Field of Research Applications; and
              (ii) HTS is not restricted from licensing or sublicensing the
              technology by an agreement which HTS may have with a third party.

1.10.         Instrument means a device that reads the events that occur in a
              Chip for use in the Field of Research Applications using Grating
              SPR Technology covered by one or more Valid Claims of the HTS
              Patents.

1.11.         Research Applications means those areas of research, including,
              but not limited to, high throughput screening, genomics and
              proteomics, for which the HTS products may be used, but excluding
              food and environmental testing and the Medical Diagnostic Fields
              defined in the HTS License Agreement with Applied Biosystems, Inc.

1.12.         Peripheral Equipment means those devices that are sold in
              conjunction with the Instrument and/or Chips, including, but not
              limited to, chemistry coating, sample preparation and Chip
              handling equipment.

2.     DISTRIBUTORSHIP OPTION TO MCC BY HTS TO DISTRIBUTE HTS PRODUCTS.

           HTS hereby grants to MCC an exclusive option to become the sole and
exclusive distributor to market, sell and distribute HTS Products for Research
Applications in Japan. MCC is entitled to fulfill such rights to distribute the
HTS SPR Array System and HTS Products through any of its wholly owned
subsidiaries.

3.     NOTIFICATION TO MCC

     3.1      Development of HTS SPR Array System: If and when the HTS SPR Array
              System is successfully developed by HTS, HTS shall promptly notify
              MCC of such fact (expected to be on or about April 1, 2001) with
              sufficient information and data, thereof MCC shall send to HTS,
              within 30 days of notice by HTS, MCC persons to evaluate within 10
              days of arrival at HTS the performance of the HTS SPR Array System
              pursuant to the specifications of Schedule A and such HTS SPR
              Array System will be delivered to MCC after such evaluation of
              performance. After such 10 days evaluation, if the HTS SPR Array
              System meets the specifications of Schedule A, MCC shall notify in
              writing whether MCC will exercise MCC'S option or not, within five
              (5) days after the end of the 10 days evaluation period
              (`'Notification Period"). In case MCC will not notify in writing
              MCC will not exercise MCC's option during Notification Period,
              Exercise Date shall be deemed on the next day of the end of
              Notification Period.

<PAGE>   3

4.     PAYMENTS

           In consideration of the exercise of the option by MCC , MCC shall pay
HTS one million and five hundred thousands US Dollars (US$1,500,000-) within
forty-five (45) days from the Exercise Date.

5.     EXECUTION OF DISTRIBUTION AGREEMENT

       If the option exercised hereunder, HTS and MCC shall enter into
distribution agreement attached hereto as Schedule D.

6.       TERM AND TERMINATION

6.1           Term of Agreement This Agreement shall commence on the Effective
              Date and continue, unless earlier terminated pursuant to
              Paragraphs 6.2, 6.3 or 6.4 of this Agreement, until (i) the
              expiration of two (2) years from the Effective Date; or (ii) the
              date of the payment pursuant to Paragraph 4 above, whichever comes
              earlier. It is hereby acknowledged that during the term of this
              Agreement, HTS may provide notice of availability of evaluation of
              the HTS Array Systems and more than one evaluation may occur
              during the term of this Agreement.

6.2           Termination by HTS. If MCC is in material default of any of its
              obligations under this Agreement, HTS shall have the right to
              terminate this Agreement by giving thirty (30) days' written
              notice of termination specifying the reason for termination,
              provided that such notice will be of no effect and termination
              will not occur if the specified default is cured prior to the
              expiration of said thirty (30) day notice period.

6.3           Termination by MCC.

           (a)    If HTS is in material default of any of its obligations under
                  this Agreement, MCC shall have the right to terminate this
                  Agreement by giving thirty (30) days' written notice of
                  termination specifying the reason for termination, provided
                  that such notice will be of no effect and termination will not
                  occur if the specified default is cured prior to the
                  expiration of said thirty (30) day notice period.

6.4           Termination Resulting from Government Action. Either party may,
              immediately upon notice, terminate this Agreement in its entirety
              or with respect to any patent license granted under the Agreement
              if: (1) such termination is necessary to comply with an order or
              official request of the government of the terminating party; or
              (2) normal conduct of the business of the other party as a private
              enterprise ceases or is substantially altered as a consequence of
              action taken by governmental or other authority.

7.     INDEMNIFICATION

           HTS shall defend, indemnify and hold MCC and its shareholders,
directors, officers, agents, representatives, successors and assigns harmless
from and against any and all claims, damages, costs (including reasonable
attorneys' fees), judgments, fines, penalties, losses, diminution in value and
liabilities of and kind or nature: (a) arising out of the breach by HTS of any
of its warranties, representations and covenants under this Agreement.

<PAGE>   4

8.     REPRESENTATIONS AND WARRANTIES

     8.1      HTS hereby warrants and represents to MCC as follows:

           (a)    HTS is a corporation duly organized, validly existing and in
                  good standing under the laws of the State of Minnesota.

           (b)    This Agreement has been duly authorized, executed and
                  delivered by HTS and constitutes a valid and binding
                  obligation of HTS, enforceable in accordance with its terms,
                  except as rights to indemnification thereunder may be limited
                  by applicable law and except as and to the extent that the
                  enforcement thereof may be limited by bankruptcy, insolvency,
                  reorganization, moratorium or other similar laws relating to
                  or affecting creditors' rights generally or by general
                  equitable principles. The execution, delivery and performance
                  of this Agreement and the consummation of the transactions
                  contemplated thereby have been authorized by all necessary
                  corporate action and do not and will not conflict with or
                  result in any material breach of any of the provisions of, or
                  constitute a material default under, or result in a material
                  violation of, or require any authorization, consent or
                  approval, under the provisions of any organizational charter,
                  articles, by-laws, member control, operating or other
                  agreement, contract or instrument to which HTS is bound or
                  affected, or any law, statute, rule, regulation, judgment
                  order or decree to which HTS is subject.

           (c)    HTS is the sole and exclusive licensee, sublicensee or owner,
                  as the case may be, of all the rights of HTS Patents listed in
                  Schedules B and C, and has full right, power and authority to
                  grant the option under this Agreement.

           (d)    All HTS Patents listed in Schedule B are in force having paid
                  all necessary maintenance fees. HTS has no knowledge of
                  information that would render any of the listed patents
                  invalid or unenforceable.

           (e)    HTS has good and marketable title to the HTS Patents free and
                  clear of any and all liens, pledges, claims, licenses,
                  assignments, conditional sales contracts, agreements or
                  encumbrances of any kind that would impair HTS's ability to
                  grant the licenses under this Agreement.

<PAGE>   5

     8.2      MCC hereby warrants and represents to HTS as follows:

            (a)   MCC is a corporation duly organized, validly existing and in
                  good standing under the laws of Japan.

            (b)   This Agreement has been duly authorized executed and delivered
                  by MCC and constitutes a valid and binding obligation of MCC,
                  enforceable in accordance with its terms, except as rights to
                  indemnification thereunder may be limited by applicable law
                  and except as the enforcement thereof may be limited by
                  bankruptcy, insolvency, reorganization, moratorium or other
                  similar laws relating to or affecting creditors' rights
                  generally or by general equitable principles. The execution,
                  delivery and performance of this Agreement and the
                  consummation of the transactions contemplated thereby do not
                  and will not conflict with or result in any material breach of
                  any of the provisions of, or constitute a material default
                  under, or result in a material violation of, or require any
                  authorization, consent or approval, under the provisions of
                  the Laws of Japan or articles of incorporation of MCC or other
                  agreement, contract or instrument to which MCC is bound or
                  affected, or any law, statute, rule, regulation, judgment
                  order or decree to which MCC is subject.

9.     MISCELLANEOUS

     9.1      Assignment. Neither party may assign or otherwise transfer its
              rights and obligations under this Agreement without the prior
              written consent of the other party, to any third party; provided,
              however, that either party may assign this Agreement and/or any of
              the rights granted hereunder without such consent (i) to its
              wholly owned subsidiary, and (ii) the successor in interest (by
              merger, share exchange, combination or consolidation of any type,
              operation of Law, purchase or otherwise), if such assignee or
              successor agrees to be bound by the terms hereof.

     9.2      Entire Agreement. This Agreement, together with the Schedules,
              constitutes the entire agreement of the parties with respect to
              the subject matter hereof and supersedes all previous proposals or
              agreements, oral or written, and all negotiations, conversations
              or discussions heretofore had between the parties related to the
              subject matter of this Agreement. No modification of this
              Agreement or waiver of any of its terms shall be binding upon the
              parties unless said modification or waiver is in writing, signed
              by both parties, and states that it is an amendment to this
              Agreement.

     9.3      Survival. Paragraphs 7 and 8 shall survive termination or
              expiration of this Agreement for any reason and continue
              thereafter in full force and effect.

     9.4      Discharge. This Agreement may not be released, discharged,
              abandoned, changed or modified in any manner, except by an
              instrument in writing signed on behalf of each of the parties to
              this Agreement by their duly authorized representatives.

<PAGE>   6

    9.5       Waiver. The failure of either party to enforce at any time any of
              the provisions of this Agreement shall in no way be construed to
              be a waiver of any such provision, nor in any way to affect the
              validity of this Agreement or any part of it or the right of
              either party after any such failure to enforce each and every such
              provision. No waiver of any breach of this Agreement shall be held
              to be a waiver of any other or subsequent breach.

     9.6      Force Majeure. Neither party shall be responsible for any delay or
              failure in the performance of any obligation hereunder due to
              strikes, lockouts, fires, floods, acts of God, embargoes, wars,
              riots, or act or order of any government or governmental agency.

     9.7      Execution in Counterparts. This Agreement may be executed in one
              or more counterparts, all of which shall be considered one and the
              same agreement, and shall become a binding agreement when one or
              more counterparts have been signed by each party and delivered to
              the other party.

     9.8      Titles and Headings. The titles and headings to Sections herein
              are inserted for the convenience of reference only and are not
              intended to be a part of or to affect the meaning or
              interpretation of this Agreement.

     9.9      Construction. The parties agree that the restrictions, covenants,
              agreements and obligations contained in this Agreement are
              reasonable and necessary to protect the legitimate interests of
              the parties. This Agreement shall be construed without regard to
              any presumption or other rule requiring construction hereof
              against the party causing this Agreement to be drafted.

     9.10     Benefit. Nothing in this Agreement, expressed or implied, is
              intended to confer on any person other than the parties to this
              Agreement or their respective permitted successors or assigns, any
              rights, remedies, obligations or liabilities under or by reason of
              this Agreement.

     9.11     Notices. All notices, statements, reports, requests or other
              communications to a party required or permitted hereunder shall be
              in writing and shall be deemed effective and properly given when
              sent by registered or certified mail, or by confirmed facsimile
              transmission to the person as indicated below or such other person
              as may be designated by MCC or HTS by such notice;

              if to MCC, to:
              Mitsubishi Chemical Corporation.
              5-2, Marunouchi 2-chome,
              Chiyoda-ku, Tokyo 100-0005 Japan
              Attention:  General Manager, Life Science Business Initiatives
                          Department
              Facsimile number:  (03) 3283-5809

              and, if to HTS, to:
              HTS BioSystems, Inc.,
              92 South Street,
              Hopkinton, Massachusetts 01748 U.S.A.
              Attention:  CEO
              Facsimile number:  (508) 435-6342

<PAGE>   7

              MCC and HTS may change their respective above-specified recipient
              and/or mailing address by notice to the other party given in the
              manner herein prescribed. All notices shall be deemed given on the
              day when actually delivered as provided above (if delivered by
              facsimile) or on the day shown on the return receipt (if delivered
              by mail).

     9.12     Severability. If any provision of this Agreement is held invalid
              by a court of competent jurisdiction, the remaining provisions
              shall nonetheless be enforceable according to their terms.
              Further, if any provision is held to be overbroad as written, such
              provision shall be deemed amended to narrow its application to the
              extent necessary to make the provision enforceable according to
              applicable law and shall be enforced as amended.
     9.13     Governing Law. This Agreement shall be construed in accordance
              with the laws of the State of New York, excluding its choice of
              law provisions. The parties further agree to submit themselves to
              the non-exclusive jurisdiction of the state and federal courts of
              the State of New York in the event that any dispute arises under
              this Agreement.

           IN WITNESS WHEREOF, each of the parties has caused this Agreement to
be executed in the manner appropriate to each as of the Effective Date.

                                       MITSUBISHI CHEMICAL CORPORATION

                                       -----------------------------------------
                                       By:  Kiyoshi Nakayama
                                       Its: General Manager,
                                            Life Science Business Initiatives
                                            Department

                                       HTS BIOSYTEMS, INC.

                                       -----------------------------------------
                                       By:  Gregory G. Freitag
                                       Its: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]